Skip to content

Efficacy of ESWT Combined With rTMS Under the Central–Peripheral–Central Closed-Loop Framework in Managing Post-Stroke Elbow Flexor Spasticity: A Randomized Controlled Trial

Efficacy of ESWT Combined With rTMS Under the Central–Peripheral–Central Closed-Loop Framework in Managing Post-Stroke Elbow Flexor Spasticity: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600129010
Enrollment
Unknown
Registered
2026-07-29
Start date
2026-08-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

C group:Conventional occupational therapy (Occupational Therapy, OT) combined with repetitive transcranial magnetic stimulation (rTMS) stimulation
D group:Conventional occupational therapy (OT), extracorporeal shock wave therapy (ESWT), and repetitive transcranial magnetic stimulation (rTMS) with sham stimulation
A group:Only conduct regular occupational therapy (Occupational Therapy, OT)
B group:Conventional occupational therapy (OT), extracorporeal shock wave therapy (ESWT), and repetitive transcranial magnetic stimulation (rTMS) stimulation

Sponsors

Beijing Haidian Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Meet the diagnostic criteria of the 2023 Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke; 2.First-ever stroke, with onset between 2 weeks and 6 months prior to enrollment, and unilateral limb hemiplegia; 3.Aged 18 to 80 years; 4.Stable vital signs; 5.Alert and conscious, with no severe cognitive impairment, able to cooperate with treatment; 6.Increased flexor elbow muscle tone, with a Modified Ashworth Scale (MAS) score of 1 to 3; 7.Provide written informed consent prior to treatment; 8.No other neurological diseases;

Exclusion criteria

Exclusion criteria: 1.Fracture or severe osteoporosis; 2.Severe bleeding tendency or coagulation disorders; 3.Presence of metallic implants or cardiac pacemaker; 4.Severe cognitive impairment or communication disorders preventing cooperation; 5.Receipt of botulinum toxin type A injection to the affected upper limb, and/or oral antispastic medication, and/or surgical intervention for spasticity within the past 6 months; 6.Skull defect; 7.Skin lesions on the affected upper limb; 8.Pregnancy, brain tumor, meningitis, epilepsy, or severe cardiac, hepatic, pulmonary, or renal insufficiency; 9.Allergy to electroencephalography (EEG) gel;

Design outcomes

Primary

MeasureTime frame
Modified Ashworth Scale;

Secondary

MeasureTime frame
Ultrasound elastography parameters;Modified Tardieu Scale;Fugl-Meyer Assessment of Upper Extremity;Modified Barthel Index;Visual Analogue Scale;36?Item Short?Form Health Survey (SF?36);Simultaneous EEG?EMG recording;

Countries

China

Contacts

Public ContactGao Yang

Beijing Haidian Hospital

945188288@qq.com+86 10 82693564

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026